PT 141, sometimes referred to as PT-141 and most recently under the name Bremelanotide is a 7 amino acid peptide that derived from Melanotan II. Melanotan II (MT2) was developed for the purpose of promoting tanning, but more than 90% of all subjects during testing were found to have increases in libido, performance and sexual satisfaction. itused to treat hypoactive sexual desire disorder in premenopausal women. PT 141 does not interact with alcohol. The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown. Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141. Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. Bremelanotide was granted FDA approval on 21 June 2019.